[go: up one dir, main page]

MA29722B1 - Schema posologique pour le prasugrel - Google Patents

Schema posologique pour le prasugrel

Info

Publication number
MA29722B1
MA29722B1 MA30577A MA30577A MA29722B1 MA 29722 B1 MA29722 B1 MA 29722B1 MA 30577 A MA30577 A MA 30577A MA 30577 A MA30577 A MA 30577A MA 29722 B1 MA29722 B1 MA 29722B1
Authority
MA
Morocco
Prior art keywords
prasugrel
dosage
dosage scheme
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA30577A
Other languages
English (en)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29722B1 publication Critical patent/MA29722B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE UNE POSOLOGIE POUR TRAITER UNE MALADIE VASCULAIRE CHEZ UN HUMAIN, CETTE POSOLOGIE CONSISTANT À ADMINISTRER UN DOSE DE CHARGE D'ENVIRON 30 MG À 70 MG DE PRASUGREL OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET À ADMINISTRER ENSUITE QUOTIDIENNEMENT ENVIRON 7.5 MG À 15 MG COMME DOSE D'ENTRETIEN DE PRASUGREL OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI.
MA30577A 2005-06-17 2008-01-16 Schema posologique pour le prasugrel MA29722B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
MA29722B1 true MA29722B1 (fr) 2008-09-01

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30577A MA29722B1 (fr) 2005-06-17 2008-01-16 Schema posologique pour le prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (fr)
EP (1) EP1893205A4 (fr)
JP (1) JP2008543853A (fr)
KR (1) KR20080016647A (fr)
CN (1) CN101198329A (fr)
AU (1) AU2006259538A1 (fr)
BR (1) BRPI0612624A2 (fr)
CA (1) CA2612315A1 (fr)
EA (1) EA200800075A1 (fr)
EC (1) ECSP078014A (fr)
GT (1) GT200600263A (fr)
IL (1) IL187486A0 (fr)
MA (1) MA29722B1 (fr)
MX (1) MX2007015430A (fr)
NO (1) NO20080244L (fr)
TN (1) TNSN07474A1 (fr)
WO (1) WO2006138317A2 (fr)
ZA (1) ZA200710769B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物
EP2152078B8 (fr) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Préparations contenant du clopidogrel et de la sulfoalkyl-éther cyclodextrine et méthodes d'utilisation
WO2010132711A1 (fr) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant des dérivés de prasugrel et de cyclodextrine, leurs procédés de préparation et méthodes d'utilisation
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (fr) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel à désintégration orale
WO2016203018A1 (fr) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques de bromhydrate de prasugrel
WO2018167447A1 (fr) * 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HU227746B1 (en) * 2000-07-06 2012-02-28 Ube Industries Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
EP1350511B1 (fr) * 2000-12-25 2008-09-10 Daiichi Sankyo Company, Limited Compositions medicales contenant de l'aspirine
EP1660183A2 (fr) * 2003-05-05 2006-05-31 Eli Lilly and Company Traitement des maladies cardiovasculaires avec une substance de formule 1 (cs 747-prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
TNSN07474A1 (en) 2009-03-17
WO2006138317A2 (fr) 2006-12-28
IL187486A0 (en) 2008-06-05
ECSP078014A (es) 2008-01-23
EP1893205A4 (fr) 2010-06-30
ZA200710769B (en) 2009-09-30
AU2006259538A1 (en) 2006-12-28
JP2008543853A (ja) 2008-12-04
EP1893205A2 (fr) 2008-03-05
EA200800075A1 (ru) 2008-04-28
GT200600263A (es) 2007-02-23
KR20080016647A (ko) 2008-02-21
NO20080244L (no) 2008-01-14
CA2612315A1 (fr) 2006-12-28
US20090156632A1 (en) 2009-06-18
MX2007015430A (es) 2008-02-21
WO2006138317A3 (fr) 2007-05-03
CN101198329A (zh) 2008-06-11
BRPI0612624A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
MA29722B1 (fr) Schema posologique pour le prasugrel
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
ZA200802811B (en) Therapy for the treatment of disease
WO2007053661A3 (fr) Utilisations d'anticorps anti-cd40
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007087151A3 (fr) Méthode de traitement d'un dysfonctionnement cognitif
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2008030830A3 (fr) Composition à libération prolongée et son procédé d'utilisation
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
ZA200609266B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
CA2632207C (fr) Utilisation de calcitonine pour traiter la pr
TW200616644A (en) Medicine for prevention or treatment of diabetes
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
WO2008057599A3 (fr) Procédés de traitement de troubles associés à l'abeta et compositions
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.